Truist Securities Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $60
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has initiated coverage on Protagonist Therapeutics with a Buy rating and set a price target of $60.
September 09, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has initiated coverage on Protagonist Therapeutics with a Buy rating and a price target of $60, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $60 by Truist Securities suggests a positive sentiment towards Protagonist Therapeutics. This is likely to boost investor confidence and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100